Likewise, despite encouraging results in animal models, a 1-year clinical trial using the non-selective COX inhibitor ibuprofen showed no significant overall effects on cognitive and clinical outcomes in patients with mild-to-moderate AD (although positive results were seen in APOE ε4 carriers, with the opposite pattern observed in non-carriers) [161]. Here, APOE is linked to Alzheimer disease.